Différences

Ci-dessous, les différences entre deux révisions de la page.

--- ecolopol:covid19 [2020/04/24 19:25] – [Données et retours d'expériences autour de l'hydroxychloroquine] Grégory Gutierez
+++ ecolopol:covid19 [2020/04/25 10:35] – [Données et retours d'expériences autour de l'hydroxychloroquine] Grégory Gutierez
@@ Ligne 329: / Ligne 329: @@
 ===== Données et retours d'expériences autour de l'hydroxychloroquine =====
+^[[https://www.theguardian.com/world/2020/apr/24/chloroquine-study-coronavirus-brazil|Brazilian chloroquine study halted after high dose proved lethal for some patients]]^The Guardian^24/04/20^
+|Researchers planned to assess their outcomes after 28 days. But after 13 days, six of 40 patients in the low-dose group had died, compared with 16 of 41 patients in the high-dose group. Furthermore, five patients in the high-dose group had underlying heart disease, three of whom died. //“Despite these discouraging findings, several other observations prevent concluding categorically that high-dose chloroquine was toxic,”// authors of a comment article said. Hydroxychloroquine and chloroquine in combination with azithromycin were first put forward as potential treatments for Covid-19 in a French study described as //“meaningless”//. The journal later said the study did not meet standards for publication. (...) Despite the lack of evidence that it is an effective treatment for Covid-19, some American hospitals have used hydroxychloroquine to treat seriously ill patients in the hope of some benefit. However, scientists have repeatedly urged caution. |||
 ^[[https://www.mediapart.fr/journal/france/230420/chloroquine-de-plus-en-plus-de-complications-cardiaques-signalees|Chloroquine: de plus en plus de complications cardiaques signalées]]^Médiapart.fr^23/04/20^